US Oncologist Survey: Optimizing Treatment for Advanced MelanomaThe Assessment GroupNovember 2, 2011 50 Pages - SKU: TAG3958723 |
- Executive Summary
- Chapter 1: Introduction
- Table 1. Treatment Options in Advanced Melanoma
- Chapter 2: Respondent Demographics
- Table 2. Eligibility Criteria for Survey Participation
- Medical specialty
- Attended medical school in the US
- Gender of survey respondents
- Geographic settings
- Practice settings
- Minimal acceptable level of evidence in determining treatment regimen
- Chapter 3: Treatment of Stage III Melanoma with Micrometastatic Axillary Nodes
- Confidence in treating this patient to an optimal outcome
- Next step in management
- Laboratory studies to order
- First-line chemotherapy regimen
- Factors influencing treatment decision
- Second-line treatment regimen
- Factors influencing treatment decision
- Chapter 4: Treatment of Elderly Woman with Metastatic Disease at the Time of Diagnosis
- Confidence in treating this patient to an optimal outcome
- Laboratory studies to order
- BRAF Mutation Description
- First-line chemotherapy regimen
- Expected response rate with vemurafenib (PLX4032)
- Anticipated complications expected following treatment with vemurafenib (PLX4032)
- Chapter 5: Young Man with Recurrent Melanoma Metastatic to Liver and Bone
- Confidence in treating this patient to an optimal outcome
- Laboratory studies to order
- First-line chemotherapy regimen
- Mechanism of action of Yervoy (ipilimumab)
- Managing side effect of treatment
- Next step in management
- Proprietary and confidential report prepared by The Assessment Group | 2090 Columbiana Road, Ste 4700 | Birmingham, AL 35216 | 205-776-2701
- Reproducation without prior written permission, in any media now in existence or hereafter developed in whole or in any part, is strictly prohibited.
- Page 5
- Chapter 6: Patient with solitary metastatic lesion
- Confidence in treating patient to an optimal outcome
- First-line chemotherapy regimen
- Factors influencing treatment decisions
- Next step in management
- Barriers to an optimal outcome
- Chapter 7: Summary
- Appendix A: Survey Instrument
More Oncology/Hematology reports by The Assessment Group
US Market Changes in the Treatment of Advanced Melanoma by The Assessment Group
Progressively unfolding patient case scenarios were presented to 200 U.S. oncologists, who manage patients with advanced melanoma, to understand differences in clinical decisions and the ...
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma by The Assessment Group
The purpose of this research study is to examine the current and evolving practice patterns of oncologists in managing advanced non-Hodgkin’s lymphoma. A survey ...
US Market Changes in the Treatment of Advanced Prostate Cancer by The Assessment Group
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. ...
US Market Changes in the Treatment of Advanced Lung Cancer by The Assessment Group
See all reports like this >>The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal ...
More United States Oncology/Hematology reports
US Cancer Diagnostics Market: Innovative Technologies and Emerging Business Opportunities by Venture Planning Group
This report contains 620 pages, 103 tables and presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory ...
US Proton Therapy Market Analysis to 2017 by RNCOS
According to most Oncologists, about 60% of all cancer patients undergo some sort of radiation therapy during their course of treatment. Despite advances in technology ...
United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery by Frost & Sullivan
Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. In Oncology, developers are interested in understanding the opportunities and ...
The US Hematology Market: Instrument and Consumable Sales Forecasts by Market Segment, Key Supplier Shares by Venture Planning Group
See all reports like this >>This report provides an overview of the US hematology market, including sales and market shares of leading instrument and consumable suppliers, as well as test ...
More United States reports
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by Mintel - Snapshots
See all reports like this >>Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
- Facilities
- Physicians' Offices
- Insurance & Managed Care
- Disease Management
- Therapeutic Area
- Oncology/Hematology

